Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice

被引:162
作者
Kawada, M
Ohno, Y
Ri, Y
Ikoma, T
Yuugetu, H
Asai, T
Watanabe, M
Yasuda, N
Akao, S
Takemura, G
Minatoguchi, S
Gotoh, K
Fujiwara, H
Fukuda, K
机构
[1] Gifu Univ, Sch Med, Dept Internal Med 2, Gifu 5008705, Japan
[2] Gifu Univ, Sch Med, Dept Oriental Med, Gifu 5008705, Japan
关键词
apoptosis; gallic acid; lung cancer;
D O I
10.1097/00001813-200111000-00009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We previously reported that gallic acid (3,4,5-trihydroxybenzoic acid), a naturally occurring plant phenol, can induce apoptosis in four kinds of human lung cancer cell lines in vitro. The present study further investigated the In vivo anti-tumor effects of orally administered gallic acid. Gallic acid reduced cell viability of LL-2 mouse lung cancer cells in vitro dose dependently, with a 50% inhibitory concentration (IC50) value of around 200 muM. C57Black mice were transplanted with LL-2 cells, and administered gallic acid (1 mg/ml in drinking water, ad libitum) and/or cisplatin (4 mg/kg i.p. injection, once a week). The average weight of the transplanted tumors, obtained at 29 days after transplantation, in the mice of control, gallic acid-treated cisplatin-treated and cisplatin plus gallic acid-treated groups was 4.02, 3.65, 3.19 and 1.72 g, respectively. The average tumor weight of the mice treated with cisplatin combined with gallic acid was significantly smaller than that of the control group (p<0.05). The amount of apoptotic cells in the tumor tissues of mice treated with gallic acid and/or cisplatin was significantly higher than those of the control mice. Combination of gallic acid and cisplatin increased the tumor cell apoptosis compared with the treatment with cisplatin alone. The present findings suggest that the combination of gallic acid with an anti-cancer drug, including cisplatin, may be an effective protocol for lung cancer therapy. [(C) 2001 Lippincott Williams & Wilkins.].
引用
收藏
页码:847 / 852
页数:6
相关论文
共 32 条
[1]  
BONI C, 1989, CANCER, V63, P638, DOI 10.1002/1097-0142(19890215)63:4<638::AID-CNCR2820630406>3.0.CO
[2]  
2-8
[3]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[4]  
Bonomini M, 1997, ITAL J MINER ELECT M, V11, P9
[5]   New combinations in the treatment of lung cancer - A time for optimism [J].
Bunn, PA ;
Kelly, K .
CHEST, 2000, 117 (04) :138S-143S
[6]  
Fujinaga S., 1994, SHOWA U J MED SCI, V6, P135
[7]   IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[8]   RE-EXAMINATION AND FURTHER DEVELOPMENT OF A PRECISE AND RAPID DYE METHOD FOR MEASURING CELL-GROWTH CELL KILL [J].
HANSEN, MB ;
NIELSEN, SE ;
BERG, K .
JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 119 (02) :203-210
[9]   Apoptosis-inducing activity of high molecular weight fractions of tea extracts [J].
Hayakawa, S ;
Kimura, T ;
Saeki, K ;
Koyama, Y ;
Aoyagi, Y ;
Noro, T ;
Nakamura, Y ;
Isemura, M .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2001, 65 (02) :459-462
[10]  
Hillman GG, 2001, CLIN CANCER RES, V7, P382